The burden of multiple myeloma: Assessment on occurrence, outcomes and cost using a retrospective longitudinal study based on administrative claims database

Italian Journal of Public Health

Volumn 8, Issue 4, 2011, Pages 325-330

  de Portu, Simona ^a   Fanin, Renato ^b   Patriarca, Francesca ^b   Morsanutto, Andrea ^c   Tosolini, Francesca ^c   Esti, Renato ^c   Mantovani, Lorenzo G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c Servizio di Valutazione di Impatto Ambientale   (Italy)

Author keywords

Administrative database; Cost; Incidence; Multiple myeloma

Indexed keywords

EID: 84255172629     PISSN: 17237815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wisløff F, Eika S, Hippe E et al. Measurement of healthrelated quality of life in multiple myeloma. Br J Haematol 1996;92:604-13.
2. Alexander DD, Mink PJ, Adami H et al. Multiple myeloma: A review of the epidemiologic literature. Int J Cancer 2007;120:40-61.
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
4. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
5. Katze JA, Hari P, Vesole DH. Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 2007;57:301-18.
6. Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
7. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
8. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
9. Dimopoulos MA, Spencer A, Attal M et al. Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010). Blood 2005;106:230a(abstr 6).
10. Weber D, Chen C, Niesvizky R et al. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009). J Clin Oncol 2006;24(suppl):427s (abstr 7521).
11. Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial. Lancet 2006;367:825-31.
12. Rajkumar SV, Hayman SR, Lacy MQ et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
13. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
14. Ministry of Health. Decree 14th December 1994. "Tariffe delle prestazioni di assistenza ospedaliera". Suppl. to "Gazzetta Ufficiale" n. 209, 8th September 1997
15. Italian National Therapeutic Formulary, 2000 and subsequently updating.
16. DGR n. 1276, 2 may 1997 and subsequently updatng.
17. Auguston BM, Begum G, Dunn JA et al. Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-26.
18. Rajkumar SV, Blood E, Vesole D et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.
19. Kumar S, Anderson KC. Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol 2005;2:262-70.
20. Kumar SK, Rajkumar V, Dispensieri A et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-20.